TY - JOUR
AU - Hirschel, Bernard
AB - Abstract Objectives: Determine whether patients who have acquired the human immunodeficiency virus through injecting drug use receive less antiviral medication (zidovudine) than comparable patients of other risk groups considering access to, acceptance of, and compliance with treatment. Design: Historical cohort study. Setting: Human immunodeficiency virus outpatient clinic. Patients: Human immunodeficiency virus—infected subjects eligible for zidovudine treatment between January 1, 1989, and January 1, 1992, comparing injecting drug users (IDUs) with non-IDUs ("others"). Main Outcome Measures: Proposal, acceptance, start of, and compliance with zidovudine treatment. Results: One hundred fifty-one IDUs and 162 other human immunodeficiency virus—positive subjects became eligible for zidovudine treatment between January 1, 1989, and January 1, 1992. Both groups were proposed zidovudine as often, but zidovudine treatment was refused by 14.9% of IDUs compared with 7.1% of others (P=.029). The IDUs needed considerably more time than other subjects to accept zidovudine therapy (median delay between indication and start of zidovudine treatment, 61 days vs 30 days, P=.0001). After accepting, IDUs were as compliant with treatment as others: 81.3% vs 83.2% were good compliers, and rises of mean corpuscular volume of erythrocytes after 3 and 6 months of treatment were similar in both groups. Former drug users and IDUs receiving methadone were started on zidovudine treatment more often and complied better with treatment than active drug users. Absence of housing and presence of psychiatric diagnosis (both more prevalent in IDUs) were associated with less zidovudine treatment and worse compliance. Conclusion: Injecting drug users tend to delay the start of zidovudine treatment. However, once they have started, their compliance is no worse than the compliance of patients from other risk groups. These results have important implications for clinical trials, medical care, and public health.(Arch Intern Med. 1994;154:1121-1127) References 1. Des Jarlais DC, Friedman SR, Choopanya K, Vanichseni S, Ward TP. International epidemiology of HIV and AIDS among injecting drug users . AIDS. 1992; 6:1053-1068.Crossref 2. Robert CF, Déglon JJ, Wintsch J, et al. Behavioral changes in intravenous drug users in Geneva: rise and fall of HIV infection, 1980-1989 . AIDS . 1990;4:657-660.Crossref 3. Estermann J, Sulliger JM, Skarabis H. Epidemiology of HIV infections in Switzerland and the German Federal Republic—contribution of official surveillance systems, of anonymous testing and of blood donor screening . Gesundheitswesen . 1992;54:122-126. 4. Stein MD, Piette J, Mor V, et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons . J Gen Intern Med. 1991;6:35-40.Crossref 5. Rosenberg PS, Gail MH, Schrager LK, et al. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups . J Acquir Immune Defic Syndr. 1991;4:392-401. 6. Easterbrook PJ, Keruly JC, Creagh Kirk T, Richman DD, Chaisson RE, Moore RD. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease: zidovudine epidemiology study group . JAMA . 1991; 266:2713-2718.Crossref 7. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection . N Engl J Med. 1992;327:1697-1703.Crossref 8. Lagakos S, Fischl MA, Stein DS, Lim L, Volberding P. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection . JAMA. 1991;266:2709-2712.Crossref 9. El Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS . JAMA . 1992;267:954-957.Crossref 10. Hughes JR. Exclusion of 'noncompliant' individuals from clinical trials . Controlled Clin Trials. 1993;13:176-177.Crossref 11. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs . Am Rev Respir Dis. 1991;144:745-749.Crossref 12. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic . Am J Med. 1992;92:495-502.Crossref 13. Samucels JE, Hendrix J, Hilton M, Marantz PR, Sloan V, Small CB. Zidovudine therapy in an inner city population . J Acquir Immune Defic Syndr. 1990;3: 877-883. 14. Torres RA, Mani S, Altholz J, Brickner PW. Human immunodeficiency virus infection among homeless men in a New York City shelter: association with Mycobacterium tuberculosis infection . Arch Intern Med. 1990;150:2030-2036.Crossref 15. Craven DE, Liebman HA, Fuller J, et al. AIDS in intravenous drug users: issues related to enrollment in clinical trials . J Acquir Immune Defic Syndr. 1990;3 ( (suppl 2) ):S45-S50. 16. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment orogram . Ann Intern Med. 1989;111:761-763.Crossref 17. O Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care . Am J Med. 1992;93:382-386.Crossref 18. Heald A, Flepp M, Chave JP, et al. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS: the Swiss HIV Cohort Study . Ann Intern Med. 1991;115:760-763.Crossref 19. Hirschel B. Le SIDA, Guide du Praticien . Geneva, Switzerland: Editions Médecine et Hygiène; 1991. 20. Sande MA, Volberding PA. The Medical Management of AIDS . Philadelphia, Pa: WB Saunders Co; 1990. 21. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance . Ann Intern Med. 1984;100:258-268.Crossref 22. Sadovsky R. Psychosocial issues in symptomatic HIV infection . Am Fam Physician. 1991;44:2065-2072. 23. Gerbert B, Maguire BT, Bleecker T, Coates TJ, McPhee SJ. Primary care physicians and AIDS. Attitudinal and structural barriers to care . JAMA . 1991;266: 2837-2842.Crossref 24. Skelton WP, Skelton NK. Observations concerning the use of zidovudine in an outpatient setting . Arch Intern Med. 1991;151:1238-1239.Crossref 25. Corelli RL, Guglielmo BJ, Kapusnik Uner JE, McMaster JR, Greenblatt RM. Medication usage patterns in patients with human immunodeficiency virus infection: a comparison of patient-reported medication usage with medical chart review . DICP . 1991;25:1374-1378. 26. Lim LL. Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine . Biometrics. 1992;48:619-630.Crossref
TI - A Cohort Study of Drug Users' Compliance With Zidovudine Treatment
JF - Archives of Internal Medicine
DO - 10.1001/archinte.1994.00420100105014
DA - 1994-05-23
UR - https://www.deepdyve.com/lp/american-medical-association/a-cohort-study-of-drug-users-compliance-with-zidovudine-treatment-b1QiRd5utn
SP - 1121
EP - 1127
VL - 154
IS - 10
DP - DeepDyve
ER -